This is a summary of a publication about the DESTINY-Breast03 study, which was published in the New England Journal of Medicine in March 2022. The study included 524 adults with advanced breast cancer that is HER2-positive, which means it has high levels of a protein called HER2. All of the participants in this study had their cancer worsen after previously receiving treatment. The treatment that was previously given to participants was a combination of a drug called trastuzumab with a type of chemotherapy called a taxane. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than the standard treatment. The standard treatment is a drug called trastuzumab emtansine (T-DM1). The researchers looked at the results of this study before it was finished. This is a summary of those results.This Plain Language Summary of Publication article from Future Oncology summarises the results of a study called DESTINY-Breast03. The researchers wanted to find out whether a medication called trastuzumab deruxtecan could improve participant’s breast cancer more than the standard treatment (trastuzumab emtansine).

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer’ and was published in The New England Journal of Medicine. 

Visit The New England Journal of Medicine using the link to read the original article.